



**bioMérieux evolves its governance:  
Alexandre Mérieux becomes Executive Chairman.  
Pierre Boulud is appointed Chief Executive Officer.**

**Marcy l'Étoile, France, June 14<sup>th</sup>, 2023 – bioMérieux, a world leader in the field of *in vitro* diagnostics, announces an evolution in its corporate governance. As of July 1<sup>st</sup>, 2023, Alexandre Mérieux will become Executive Chairman and Pierre Boulud Chief Executive Officer.**

On a proposal of Alexandre Mérieux, Chairman and CEO, the Board of Directors of bioMérieux approved on June 13<sup>th</sup>, 2023 the appointments of Alexandre Mérieux as Executive Chairman and of Pierre Boulud as Chief Executive Officer. Pierre Boulud has been a member of the Executive Committee for seven years, including the last three years as Chief Operating Officer.

This evolution in governance separates the functions of Chairman and Chief Executive Officer. Pierre Boulud will directly lead the Executive Committee of bioMérieux to implement the Company's strategy.

In the face of major changes in the global healthcare sector, Alexandre Mérieux will focus on key issues related to global strategy. As Executive Chairman with extended responsibilities, he will continue to chair the Board of Directors, whose mission is to define and validate the Group's strategy for the successful development of bioMérieux and its team members. He will also participate in defining the strategic priorities for Corporate Social Responsibility and innovation, as well as in the recruitment of key Executives.

Alexandre Mérieux commented: "After nine years as Chief Executive Officer of bioMérieux, I am pleased to see Pierre Boulud succeed me in this position. Pierre has greatly contributed to the company's development over the past seven years and he has my full trust in leading the teams and reinforcing the company's leadership in infectious disease diagnostics. I very much look forward to continuing our close collaboration in leading the company."

Pierre Boulud stated: "I am deeply honoured by the trust Alexandre Mérieux and the Board of Directors have placed in me, and am enthusiastic about furthering the global commitment of the company and all its team members to our shared public health mission."

**Biography of Alexandre Mérieux:**

After joining bioMérieux in 2005, Alexandre Mérieux became Chief Executive Officer before being appointed Chairman and Chief Executive Officer by the Board of Directors on December 15<sup>th</sup>, 2017.

Alexandre Mérieux has also been Vice-President of Institut Mérieux since December 2008 and Chairman of the Board of Directors of Mérieux NutriSciences (a company specialized in food safety and quality, 70% owned by Institut Mérieux) since September 2013.



### **Biography of Pierre Boulud:**

After a career at Boston Consulting Group and Ipsen, Pierre Boulud joined bioMérieux in November 2016, as member of the Executive Committee, leading the business in the Asia Pacific Region. In March 2020, Pierre Boulud was appointed Chief Operating Officer of bioMérieux and the global head of the Clinical Operations.

Pierre Boulud is also a member of the Board of Directors of MedTech Europe.

### **INVESTOR CALL**

bioMérieux will hold an investor presentation on Wednesday, June 14<sup>th</sup>, 2023 at 1:30 pm Paris time (GMT+1).

The presentation will be conducted in English and will be accessible via webcast.

Webcast link:

[https://event.webcasts.com/starthere.jsp?ei=1620711&tp\\_key=89e370cafc](https://event.webcasts.com/starthere.jsp?ei=1620711&tp_key=89e370cafc)

For people unable to join the webcast URL, the presentation can be attended through below conference numbers:

France	Europe	United States
+33 (0)1 70 72 25 50	+44 (0)330 165 3655	+1 (323) 794-2575
Access code: <b>7036296</b>		

### **BIOMÉRIEUX GAME CHANGER FOR 60 YEARS**

*Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

[www.biomerieux.com](http://www.biomerieux.com).



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

### **CONTACTS**

#### **INVESTORS RELATIONS**

**bioMérieux**

Aymeric Fichet

Tel.: +33 (0)4 78 87 20 00

[investor.relations@biomerieux.com](mailto:investor.relations@biomerieux.com)

#### **MEDIA RELATIONS**

**bioMérieux**

Olivier Rescanière

Tel.: +33 (0)4 78 87 21 99

[media@biomerieux.com](mailto:media@biomerieux.com)

**Image Sept**

Claire Doligez

Tel.: +33 (0)1 53 70 74 48

[cdoligez@image7.fr](mailto:cdoligez@image7.fr)

PRESS RELEASE